Search

everythinglearnresearchcommunity

for

Search:↓

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Preventive measures and effective management are crucial for reducing skin side effects in cancer treatment.

A woman with breast cancer developed a rare condition causing excessive fine hair growth on her face and body.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.

Certain hair straighteners and dyes may increase ovarian cancer risk, especially in African American/Black women.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.

Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.

The document concludes that blocking the internal pathways that create androgens might help treat cancers that depend on sex hormones.

Paclitaxel is an effective cancer drug with side effects and potential new uses beyond cancer.

RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Testosterone therapy can help with androgen deficiency in women but should be used with caution and monitoring due to potential risks.

Hormone therapy affects cancer risks in transgender individuals differently than in cisgender people, and more research is needed to understand these risks and improve cancer screening guidelines.

Reflexology massage helps hair regrowth in women after chemotherapy.

Dermatologists should carefully manage hair loss in cancer patients to improve their quality of life.

Testosterone implants in women require pharmacological dosing to be effective and are generally safe and well-tolerated.

Fat cells are important for tissue repair and stem cell support in various body parts.

Testosterone therapy can help postmenopausal women with low sexual desire but needs more safety research and should be used with estrogen therapy.

Deep learning helps detect skin conditions and is advancing dermatology diagnosis and treatment.

Honey and bee pollen can help reduce menopausal symptoms in breast cancer patients.

Spironolactone use is not linked to an increased risk of breast cancer, but caution is advised for high-risk patients.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.